Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium
Oncotarget2017Vol. 8(45), pp. 79223–79233
Citations Over TimeTop 19% of 2017 papers
Shanly C. Seferina, Bram Ramaekers, Maaike de Boer, M. Wouter Dercksen, Franchette van den Berkmortel, Roel J.W. van Kampen, Agnès J. van de Wouw, Adri C. Voogd, Vivianne Heijnen, Manuela Joore
Abstract
Adjuvant trastuzumab in the real world can be considered cost-effective.
Related Papers
- → The Decision Rules of Cost-Effectiveness Analysis(1996)205 cited
- → Cost-Effectiveness Analysis of the Bivalent and Quadrivalent Human Papillomavirus Vaccines from a Societal Perspective in Colombia(2013)21 cited
- → A Cost-Effectiveness Analysis of the Swedish Universal Parenting Program All Children in Focus(2015)21 cited
- → Strategic Distributional Cost-Effectiveness Analysis for Improving National Cancer Screening Uptake in Cervical Cancer: A Focus on Regional Inequality in South Korea(2017)7 cited
- → Assessing the cost-effectiveness of annual COVID-19 booster vaccination in South Korea using a transmission dynamic model(2023)7 cited